- Report
- May 2026
- 193 Pages
Canada
From €4326EUR$4,850USD£3,710GBP
- Report
- May 2026
- 200 Pages
Mexico
From €4326EUR$4,850USD£3,710GBP
- Report
- February 2026
- 150 Pages
Canada
From €4326EUR$4,850USD£3,710GBP
- Report
- February 2026
- 150 Pages
China
From €4326EUR$4,850USD£3,710GBP
- Report
- February 2026
- 150 Pages
Germany
From €4326EUR$4,850USD£3,710GBP
- Report
- February 2026
- 150 Pages
India
From €4326EUR$4,850USD£3,710GBP
- Report
- February 2026
- 150 Pages
Japan
From €4326EUR$4,850USD£3,710GBP
- Report
- September 2025
- 150 Pages
Global
From €4326EUR$4,850USD£3,710GBP
- Report
- August 2026
- 160 Pages
From €2961EUR$3,320USD£2,540GBP
€3702EUR$4,150USD£3,175GBP
- Report
- August 2025
- 277 Pages
Global
From €3969EUR$4,450USD£3,404GBP
- Report
- February 2025
- 130 Pages
Global
From €4326EUR$4,850USD£3,710GBP
- Report
- September 2025
- 72 Pages
Global
From €3500EUR$4,203USD£3,107GBP
- Report
- September 2025
- 76 Pages
Global
From €3500EUR$4,203USD£3,107GBP
- Report
- September 2025
- 110 Pages
Global
From €3500EUR$4,203USD£3,107GBP
- Report
- August 2025
Global
From €4415EUR$4,950USD£3,787GBP
- Report
- April 2025
- 203 Pages
Global
From €4148EUR$4,650USD£3,557GBP
- Report
- January 2025
- 120 Pages
Global
€4990EUR$5,993USD£4,430GBP
- Report
- October 2024
- 181 Pages
Global
From €4148EUR$4,650USD£3,557GBP
- Report
- September 2024
- 89 Pages
Global
From €4148EUR$4,650USD£3,557GBP
- Report
- October 2023
- 85 Pages
United States
From €4014EUR$4,500USD£3,443GBP

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more